Art

J-GLOBAL ID：201302204556469066   Reference number：13A1649054

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

HER2陽性早期乳癌患者における標準ネオアジュバントアントラサイクリン含有およびアントラサイクリン不含化学療法処方との組合わせでのペルツズマブ+トラスツズマブ ランダム化第II相心臓安全性試験(TRYPHAENA)

Author (13)： SCHNEEWEISS A. (Univ. Hospital, Heidelberg, DEU) ,  CHIA S. (Univ. British Columbia, Vancouver, CAN) ,  HICKISH T. (Bournemouth Univ., Bournemouth, GBR) ,  HARVEY V. (Auckland City Hospital, Auckland, NZL) ,  ENIU A. (Cancer Inst. “I Chiricuta”, Cluj-Napoca, ROM) ,  HEGG R. (FMUSP, Sao Paulo, BRA) ,  TAUSCH C. (Breast Center, Zuerich, CHE) ,  SEO J. H. (Korea Univ. Guro Hospital, Seoul, KOR) ,  TSAI Y.-F. (Taipei-Veterans General Hospital, Taipei, TWN) ,  RATNAYAKE J. (Roche Products Ltd., Welwyn, GBR) ,  MCNALLY V. (Roche Products Ltd., Welwyn, GBR) ,  ROSS G. (Roche Products Ltd., Welwyn, GBR) ,  CORTES J. (Vall d’Hebron Univ. Hospital, Barcelona, ESP)
Material： Annals of Oncology  (Ann Oncol)
Volume： 24  Issue： 9  Page： 2278-2284  Publication year： Sep. 2013 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： HER-2 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=13A1649054&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (2)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (4)： Fluorouracil ,  Epirubicin ,  Cyclophosphamid ,  Docetaxel

Reference (18)：

• Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144.
• Cortés J, Fumoleau P, Bianchi GV et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 1594-1600.
• Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
• Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
• Guarneri V, Frassoldati A, Bottini A et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2- positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30: 1989-1995.

Terms in the title (14)： HER2 ,  早期乳癌 ,  患者 ,  標準 ,  アントラサイクリン ,  化学療法 ,  処方 ,  組合わせ ,  ペルツズマブ ,  トラスツズマブ ,  ランダム化 ,  第II相 ,  心臓 ,  安全性試験